303 related articles for article (PubMed ID: 23731740)
21. (18)F-FDG PET/CT mean SUV and metabolic tumor volume for mean survival time in non-small cell lung cancer.
Kurtipek E; Çayci M; Düzgün N; Esme H; Terzi Y; Bakdik S; Aygün MS; Unlü Y; Burnik C; Bekci TT
Clin Nucl Med; 2015 Jun; 40(6):459-63. PubMed ID: 25742234
[TBL] [Abstract][Full Text] [Related]
22. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
23. Prognostic value comparison between (18)F-FLT PET/CT and (18)F-FDG PET/CT volume-based metabolic parameters in patients with head and neck cancer.
Hoshikawa H; Mori T; Yamamoto Y; Kishino T; Fukumura T; Samukawa Y; Mori N; Nishiyama Y
Clin Nucl Med; 2015 Jun; 40(6):464-8. PubMed ID: 25546204
[TBL] [Abstract][Full Text] [Related]
24. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
25. Prognostic Value of Metabolic Tumor Volume and Total Lesion Glycolysis on Preoperative ¹⁸F-FDG PET/CT in Patients with Pancreatic Cancer.
Lee JW; Kang CM; Choi HJ; Lee WJ; Song SY; Lee JH; Lee JD
J Nucl Med; 2014 Jun; 55(6):898-904. PubMed ID: 24711649
[TBL] [Abstract][Full Text] [Related]
26. Prognostic value of preoperative metabolic tumor volume measured by ¹⁸F-FDG PET/CT and MRI in patients with endometrial cancer.
Chung HH; Lee I; Kim HS; Kim JW; Park NH; Song YS; Cheon GJ
Gynecol Oncol; 2013 Sep; 130(3):446-51. PubMed ID: 23791826
[TBL] [Abstract][Full Text] [Related]
27. Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma.
Fonti R; Larobina M; Del Vecchio S; De Luca S; Fabbricini R; Catalano L; Pane F; Salvatore M; Pace L
J Nucl Med; 2012 Dec; 53(12):1829-35. PubMed ID: 23071351
[TBL] [Abstract][Full Text] [Related]
28. Prognostic significance of volume-based 18F-FDG PET/CT parameter in patients with surgically resected non-small cell lung cancer. Comparison with immunohistochemical biomarkers.
Lee JY; Choi JY; Heo JH; Han J; Jang SJ; Kim K; Kim J; Shim YM; Kim BT
Nuklearmedizin; 2016; 55(1):7-14. PubMed ID: 26875430
[TBL] [Abstract][Full Text] [Related]
29. Prognostic value of preoperative metabolic tumor volume and total lesion glycolysis measured by 18F-FDG PET/CT in salivary gland carcinomas.
Ryu IS; Kim JS; Roh JL; Lee JH; Cho KJ; Choi SH; Nam SY; Kim SY
J Nucl Med; 2013 Jul; 54(7):1032-8. PubMed ID: 23670902
[TBL] [Abstract][Full Text] [Related]
30. High tumor metabolic activity as measured by fluorodeoxyglucose positron emission tomography is associated with poor prognosis in limited and extensive stage small-cell lung cancer.
Lee YJ; Cho A; Cho BC; Yun M; Kim SK; Chang J; Moon JW; Park IK; Choi HJ; Kim JH
Clin Cancer Res; 2009 Apr; 15(7):2426-32. PubMed ID: 19318478
[TBL] [Abstract][Full Text] [Related]
31. Clinical significance of pretreatment metabolic tumor volume and total lesion glycolysis in hypopharyngeal squamous cell carcinomas.
Roh JL; Kim JS; Kang BC; Cho KJ; Lee SW; Kim SB; Choi SH; Nam SY; Kim SY
J Surg Oncol; 2014 Dec; 110(7):869-75. PubMed ID: 25088392
[TBL] [Abstract][Full Text] [Related]
32. Prognostic value of metabolic tumor volume measured by 18F-fluorodeoxyglucose positron emission tomography in patients with esophageal carcinoma.
Hyun SH; Choi JY; Shim YM; Kim K; Lee SJ; Cho YS; Lee JY; Lee KH; Kim BT
Ann Surg Oncol; 2010 Jan; 17(1):115-22. PubMed ID: 19826877
[TBL] [Abstract][Full Text] [Related]
33. Prognostic superiority of the National Comprehensive Cancer Network International Prognostic Index over pretreatment whole-body volumetric-metabolic FDG-PET/CT metrics in diffuse large B-cell lymphoma.
Adams HJ; de Klerk JM; Fijnheer R; Heggelman BG; Dubois SV; Nievelstein RA; Kwee TC
Eur J Haematol; 2015 Jun; 94(6):532-9. PubMed ID: 25311082
[TBL] [Abstract][Full Text] [Related]
34. The prognostic role of PET/CT in small-cell lung cancer.
Budak E; Yanarateş A; Akgün A
Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(1):9-13. PubMed ID: 31865009
[TBL] [Abstract][Full Text] [Related]
35. Prognostic value of metabolic tumor volume measured by FDG-PET/CT in patients with cervical cancer.
Chung HH; Kim JW; Han KH; Eo JS; Kang KW; Park NH; Song YS; Chung JK; Kang SB
Gynecol Oncol; 2011 Feb; 120(2):270-4. PubMed ID: 21109300
[TBL] [Abstract][Full Text] [Related]
36. Relationship between primary lesion metabolic parameters and clinical stage in lung cancer.
Sahiner I; Atasever T; Akdemir UO; Ozturk C; Memis L
Rev Esp Med Nucl Imagen Mol; 2013; 32(6):357-63. PubMed ID: 23747221
[TBL] [Abstract][Full Text] [Related]
37. Metabolic Tumor Volume as Significant Predictor for Chemotherapy Containing PD-L1 Blocker in Extensive Stage Small Cell Lung Cancer.
Hashimoto K; Kaira K; Imai H; Miura YU; Shiono A; Mouri A; Yamaguchi OU; Kobayashi K; Kagamu H; Kuji I
Anticancer Res; 2024 Apr; 44(4):1541-1551. PubMed ID: 38537960
[TBL] [Abstract][Full Text] [Related]
38. Prognostic value of preoperative metabolic tumor volumes on PET-CT in predicting disease-free survival of patients with stage I non-small cell lung cancer.
Lin Y; Lin WY; Kao CH; Yen KY; Chen SW; Yeh JJ
Anticancer Res; 2012 Nov; 32(11):5087-91. PubMed ID: 23155285
[TBL] [Abstract][Full Text] [Related]
39. The predictive value of metabolic tumor volume on FDG PET/CT for transarterial chemoembolization and transarterial chemotherapy infusion in hepatocellular carcinoma patients without extrahepatic metastasis.
Lee JW; Yun M; Cho A; Han KH; Kim DY; Lee SM; Lee JD
Ann Nucl Med; 2015 Jun; 29(5):400-8. PubMed ID: 25652647
[TBL] [Abstract][Full Text] [Related]
40. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
